Video - Results from #70

Precision Medicine in Prostate Cancer VL

Search

PARP Inhibitors Changing the Standard of Care for Treatment of Metastatic Prostate Cancer (mCRPC) - The PROfound Study Details Oliver Sartor joins Alicia Morgans to highlight the recently published PROfound Trial. A phase III trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal agent treatments. The PROfound trial was published in the New England Journal of Medicine...
Genetically Informed Treatment for Advanced and Metastatic Prostate Cancer - Alicia Morgans Details Alicia Morgans, Associate Professor of Medicine at Northwestern University, shares her thoughts on genetically informed treatment for advanced and metastatic prostate cancer. Germline and somatic testing can have implications for patients in terms of their therapeutics and the main mutations. Morgans discusses the important germline and somatic mutations as well as the current data from clinical t...
Integrating Germline and Somatic Mutations Tests into Clinical Practice Workflows - Wassim Abida Details Wassim Abida, MD, describes his work to facilitate both better understanding of the genomic landscape of prostate cancer while simultaneously integrating new genomic information into clinical practice. In a conversation with Alicia Morgans, MD, MPH, Dr. Abida describes how to identify the subsets of patients that serve to benefit from targeted therapies, referencing the use of pembrolizumab for MS...
PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations - Maha Hussain Details Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it's intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cance...
Role of PARP Inhibitors in Prostate Cancer - Evan Yu Details Neal Shore and Evan Yu share in a discussion on the evolving role of PARP inhibitors in the treatment of mCRPC. Dr. Yu reviews the early interim results of rucaparib in the TRITON-2 study and points out the intricacies that must be considered when evaluating all the recent data involving DNA mutations. Drs. Shore and Yu discuss the class of PARP inhibitors in clinical development and what makes ea...
Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce Details (Length of Discussion: 8 min) Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency. Alan presents the molecular selection criteria, the design of the trial and the initial look at the first 85 patients in this study of he...